AMAG Pharmaceuticals’ (AMAG) Market Perform Rating Reaffirmed at Leerink Swann
Other equities analysts also recently issued reports about the company. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a neutral rating and a $18.00 price objective on the stock. ValuEngine downgraded AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Friday. B. Riley restated a hold rating and issued a $16.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, January 29th. BidaskClub upgraded AMAG Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, January 24th. Finally, Zacks Investment Research upgraded AMAG Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $19.89.
AMAG Pharmaceuticals (NASDAQ AMAG) opened at $13.25 on Friday. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20. The company has a market capitalization of $463.16, a PE ratio of -2.18 and a beta of 0.79. The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.48.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.